• €150 million investment over the 2019-2023 period in manufacturing site at Aubonne, Switzerland
• Expansion supports growth of current and future portfolio of Merck's biotech medicines for patients around the
world
AUBONNE, Switzerland, March 28, 2019 /PRNewswire/ -- Merck, a
leading science and technology company, today announced an investment of €150 million (165 million Swiss
francs) in its manufacturing site at Aubonne, Switzerland, to expand manufacturing
capacity for its biotech medicines. The investment will cover a new building dedicated to Merck biotech medicines destined for
more than 150 countries, helping to meet increasing patient needs for flagship medicines such as fertility treatment
Gonal-f®, newly launched therapies such as cancer drug Bavencio® and potential future products currently in
clinical development such as cancer investigational treatment M7824 (bintrafusp alfa*).
"This investment reflects our commitment to ensuring that our medicines always meet the highest quality standards and are
readily available to patients all over the world whenever they need them," said Belén Garijo, Member of the Executive Board of
Merck and CEO Healthcare. "It is an expression of our confidence in the future growth of our Healthcare business sector."
"With this latest investment, Merck is taking one step further towards a strong positioning of the Canton de Vaud as a Health
Valley, which already includes 360 companies, 400 laboratories and 20,000 jobs," said Philippe
Leuba, Vaud State Councillor. "Merck's presence in the Vaud canton is highly valued and this further investment will have
a lasting and positive impact on the region."
The new building will be equipped with cutting-edge technologies dedicated to aseptic filling and quality control, with an
innovative design and a flexible operations model to deliver increased productivity. The new lines for the aseptic filling of
biotech medicines will be equipped with isolator technology, representing best practice in aseptic filling to ensure the safety
of injectable medicines. One line will be dedicated to freeze-dried formulations, the other to liquid formulations. These two new
lines, as well as the new quality control labs, will replace existing infrastructure with technological upgrades and higher
capacity allowing to produce up to 27 million vials per year.
The construction of the new building is expected to be completed in 2020, with the new quality control labs operational in
2021 and the new lines for aseptic filling in 2023, following validation by regulatory authorities. Everything will be designed
to comply with the highest international standards of quality, environment, health and safety.
With the sites of Aubonne and nearby Vevey, Switzerland is Merck's prime hub for
manufacturing biotech medicines. With this latest expansion, Merck will have invested more than 1 billion
Swiss francs (€800 million) in Switzerland over the past ten years, reflecting the
strategic importance of the country, where it employs 2,300 employees across 11 locations. The Aubonne and Vevey sites are part of a network of 18 manufacturing sites worldwide dedicated to the production of Merck's
biotech and pharmaceutical medicines and serving 70 million patients across the globe each and every day.
* Bintrafusp alfa is the proposed International Nonproprietary Name (INN) for the bifunctional immunotherapy
M7824. Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to
www.merckgroup.com/subscribe to register online,
change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around
52,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and
sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging
diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck generated sales of € 14.8 billion in
66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This
is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed
company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United
States and Canada, where the business sectors of Merck operate as EMD Serono in
healthcare, MilliporeSigma in life science, and EMD Performance Materials.
Your Contact:
friederike.segeberg@merckgroup.com
Phone: +49-6151-72-6328
(Logo: https://mma.prnewswire.com/media/842717/MERCK__Logo.jpg)